Share Price and Basic Stock Data
Last Updated: November 26, 2025, 4:38 pm
| PEG Ratio | 3.35 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Beta Drugs Ltd, a prominent player in the pharmaceuticals industry, reported a stock price of ₹1,657 and a market capitalization of ₹1,673 Cr. The company has shown robust revenue growth over recent years, with sales increasing from ₹51 Cr in March 2018 to ₹227 Cr in March 2023, and further rising to ₹296 Cr in March 2024. The trailing twelve months (TTM) revenue stood at ₹386 Cr, indicating a strong upward trajectory. The quarterly sales figures also reflect this positive trend, with September 2023 sales reported at ₹141 Cr, up from ₹115 Cr in March 2023. The company’s ability to consistently enhance its sales performance underscores its effective business strategies and product offerings in a competitive market. However, the reported expenses also increased, from ₹41 Cr in March 2018 to ₹174 Cr in March 2023, which necessitates careful monitoring of cost control measures to maintain profitability.
Profitability and Efficiency Metrics
Beta Drugs Ltd exhibited impressive profitability metrics, with a net profit of ₹42 Cr reported for March 2025, an increase from ₹31 Cr in March 2023. The net profit margin stood at 11.70% for March 2025, reflecting a slight decline from the previous year’s margin of 12.32%. The company recorded an operating profit margin (OPM) of 21% in the same period, demonstrating operational efficiency despite rising costs. The interest coverage ratio (ICR) was reported at 11.60x, indicating strong capacity to meet interest obligations. Moreover, return on equity (ROE) was recorded at 25.9%, while return on capital employed (ROCE) stood at 27%. These figures highlight the company’s ability to generate substantial returns on investments and equity, positioning it favorably compared to industry averages, which typically range lower. Nevertheless, a consistent focus on improving operational efficiencies will be vital to counterbalance any potential pressures from increasing costs.
Balance Sheet Strength and Financial Ratios
Beta Drugs Ltd’s balance sheet reflects a solid financial foundation, with total assets reported at ₹436 Cr as of March 2025. The company’s reserves have increased significantly to ₹211 Cr, up from ₹113 Cr in March 2023, demonstrating a strong capacity for reinvestment. Borrowings were recorded at ₹146 Cr, indicating a moderate leverage ratio, with a total debt to equity ratio of 0.67x, which is relatively low compared to industry standards. The current ratio was reported at 3.22, suggesting robust liquidity and the ability to cover short-term liabilities comfortably. Additionally, the price-to-book value (P/BV) stood at 9.76x, indicating a premium valuation compared to typical sector benchmarks. While the strong liquidity position and substantial reserves provide a buffer against market volatility, the increasing borrowings must be monitored to avoid potential financial strain.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Beta Drugs Ltd reveals a strong promoter holding of 66.73%, indicating significant insider confidence in the company’s prospects. Foreign institutional investors (FIIs) have gradually increased their stake, reaching 0.90% as of March 2025, while domestic institutional investors (DIIs) hold 0.29%. The public segment accounts for 32.07% of the shareholding, with an increasing number of shareholders growing from 1,424 in March 2023 to 3,184 by September 2025. This expanding shareholder base suggests rising investor interest and confidence in the company’s growth trajectory. However, the relatively low institutional ownership may limit access to larger pools of capital for future expansions. Enhancing transparency and communication with investors could further bolster confidence and attract additional institutional interest.
Outlook, Risks, and Final Insight
Looking ahead, Beta Drugs Ltd is poised for continued growth, driven by its increasing sales and profitability metrics. However, the company faces risks, including rising operational expenses and potential supply chain disruptions that could impact margins. The pharmaceutical sector is also subject to regulatory challenges that may affect product approvals and market entry. Strengths such as a strong promoter holding and robust liquidity position provide a cushion against these risks. To sustain its growth momentum, the company must focus on effective cost management and strategic investments in innovation. The outlook remains positive, but careful navigation of operational challenges will be crucial in maintaining its competitive edge in the evolving pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Beta Drugs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 162 Cr. | 129 | 247/84.3 | 35.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,538 Cr. | 417 | 479/192 | 94.0 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.5 Cr. | 28.3 | 29.1/17.0 | 98.8 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,356.00 Cr | 1,182.92 | 52.67 | 202.40 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 47 | 44 | 51 | 65 | 88 | 96 | 112 | 115 | 141 | 154 | 180 | 182 |
| Expenses | 37 | 36 | 41 | 51 | 68 | 73 | 86 | 88 | 108 | 127 | 141 | 146 |
| Operating Profit | 9 | 8 | 11 | 14 | 20 | 23 | 27 | 26 | 33 | 27 | 39 | 36 |
| OPM % | 20% | 19% | 21% | 22% | 23% | 24% | 24% | 23% | 23% | 18% | 22% | 20% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 |
| Interest | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 |
| Depreciation | 2 | 2 | 3 | 4 | 3 | 4 | 5 | 6 | 5 | 4 | 6 | 7 |
| Profit before tax | 7 | 5 | 7 | 9 | 16 | 18 | 21 | 20 | 27 | 22 | 33 | 24 |
| Tax % | 27% | 14% | 21% | 30% | 28% | 27% | 25% | 25% | 25% | 25% | 25% | 26% |
| Net Profit | 5 | 4 | 5 | 7 | 12 | 13 | 16 | 15 | 20 | 17 | 24 | 18 |
| EPS in Rs | 5.07 | 4.25 | 5.13 | 6.48 | 11.63 | 12.95 | 15.67 | 14.73 | 19.67 | 16.40 | 24.20 | 17.81 |
Last Updated: May 31, 2025, 9:40 am
Below is a detailed analysis of the quarterly data for Beta Drugs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 182.00 Cr.. The value appears strong and on an upward trend. It has increased from 180.00 Cr. (Sep 2024) to 182.00 Cr., marking an increase of 2.00 Cr..
- For Expenses, as of Mar 2025, the value is 146.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 141.00 Cr. (Sep 2024) to 146.00 Cr., marking an increase of 5.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Sep 2024) to 36.00 Cr., marking a decrease of 3.00 Cr..
- For OPM %, as of Mar 2025, the value is 20.00%. The value appears to be declining and may need further review. It has decreased from 22.00% (Sep 2024) to 20.00%, marking a decrease of 2.00%.
- For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 2.00 Cr..
- For Interest, as of Mar 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Sep 2024) to 5.00 Cr., marking an increase of 3.00 Cr..
- For Depreciation, as of Mar 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.00 Cr. (Sep 2024) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Sep 2024) to 24.00 Cr., marking a decrease of 9.00 Cr..
- For Tax %, as of Mar 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Sep 2024) to 26.00%, marking an increase of 1.00%.
- For Net Profit, as of Mar 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Sep 2024) to 18.00 Cr., marking a decrease of 6.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 17.81. The value appears to be declining and may need further review. It has decreased from 24.20 (Sep 2024) to 17.81, marking a decrease of 6.39.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:40 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 66 | 91 | 116 | 184 | 227 | 296 | 362 | 386 |
| Expenses | 41 | 54 | 73 | 91 | 141 | 174 | 236 | 288 | 309 |
| Operating Profit | 9 | 12 | 18 | 25 | 43 | 53 | 60 | 75 | 77 |
| OPM % | 19% | 18% | 20% | 21% | 23% | 23% | 20% | 21% | 20% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 6 |
| Interest | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 7 | 12 |
| Depreciation | 2 | 3 | 4 | 7 | 7 | 10 | 10 | 13 | 15 |
| Profit before tax | 7 | 8 | 12 | 16 | 34 | 41 | 49 | 57 | 56 |
| Tax % | 1% | -2% | 21% | 27% | 28% | 25% | 25% | 26% | |
| Net Profit | 7 | 8 | 9 | 12 | 25 | 31 | 36 | 42 | 42 |
| EPS in Rs | 7.43 | 8.84 | 9.33 | 11.60 | 24.58 | 30.42 | 36.08 | 42.02 | 41.51 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 14.29% | 12.50% | 33.33% | 108.33% | 24.00% | 16.13% | 16.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -1.79% | 20.83% | 75.00% | -84.33% | -7.87% | 0.54% |
Beta Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | 25% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 37% |
| 3 Years: | 23% |
| TTM: | 26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 87% |
| 3 Years: | 36% |
| 1 Year: | 12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 27% |
| Last Year: | 26% |
Last Updated: September 5, 2025, 12:45 am
Balance Sheet
Last Updated: November 9, 2025, 1:44 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 24 | 32 | 48 | 59 | 83 | 113 | 148 | 187 | 211 |
| Borrowings | 8 | 20 | 23 | 17 | 21 | 20 | 15 | 138 | 146 |
| Other Liabilities | 9 | 22 | 28 | 31 | 45 | 55 | 82 | 101 | 121 |
| Total Liabilities | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 488 |
| Fixed Assets | 13 | 18 | 44 | 40 | 55 | 63 | 65 | 89 | 112 |
| CWIP | 1 | 15 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Other Assets | 35 | 50 | 63 | 74 | 102 | 135 | 190 | 347 | 376 |
| Total Assets | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 488 |
Below is a detailed analysis of the balance sheet data for Beta Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 211.00 Cr.. The value appears strong and on an upward trend. It has increased from 187.00 Cr. (Mar 2025) to 211.00 Cr., marking an increase of 24.00 Cr..
- For Borrowings, as of Sep 2025, the value is 146.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 138.00 Cr. (Mar 2025) to 146.00 Cr., marking an increase of 8.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 121.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 101.00 Cr. (Mar 2025) to 121.00 Cr., marking an increase of 20.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 488.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 436.00 Cr. (Mar 2025) to 488.00 Cr., marking an increase of 52.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 112.00 Cr.. The value appears strong and on an upward trend. It has increased from 89.00 Cr. (Mar 2025) to 112.00 Cr., marking an increase of 23.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 376.00 Cr.. The value appears strong and on an upward trend. It has increased from 347.00 Cr. (Mar 2025) to 376.00 Cr., marking an increase of 29.00 Cr..
- For Total Assets, as of Sep 2025, the value is 488.00 Cr.. The value appears strong and on an upward trend. It has increased from 436.00 Cr. (Mar 2025) to 488.00 Cr., marking an increase of 52.00 Cr..
Notably, the Reserves (211.00 Cr.) exceed the Borrowings (146.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 1.00 | -8.00 | -5.00 | 8.00 | 22.00 | 33.00 | 45.00 | -63.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 139 | 128 | 106 | 90 | 101 | 98 | 103 |
| Inventory Days | 37 | 104 | 102 | 100 | 87 | 106 | 122 | 127 |
| Days Payable | 81 | 143 | 119 | 127 | 123 | 139 | 145 | 152 |
| Cash Conversion Cycle | 60 | 100 | 111 | 79 | 53 | 68 | 75 | 79 |
| Working Capital Days | 50 | 40 | 56 | 76 | 61 | 73 | 80 | 82 |
| ROCE % | 18% | 21% | 22% | 36% | 34% | 33% | 27% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| Diluted EPS (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| Cash EPS (Rs.) | 54.42 | 48.08 | 42.78 | 33.37 | 19.34 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 195.25 | 163.43 | 127.82 | 96.05 | 71.37 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 195.25 | 163.43 | 127.82 | 96.05 | 71.37 |
| Revenue From Operations / Share (Rs.) | 358.96 | 307.59 | 236.24 | 191.22 | 120.79 |
| PBDIT / Share (Rs.) | 80.28 | 63.82 | 56.05 | 45.20 | 26.26 |
| PBIT / Share (Rs.) | 67.89 | 53.65 | 45.22 | 37.65 | 19.11 |
| PBT / Share (Rs.) | 56.44 | 50.71 | 42.70 | 35.68 | 16.59 |
| Net Profit / Share (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| NP After MI And SOA / Share (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| PBDIT Margin (%) | 22.36 | 20.74 | 23.72 | 23.63 | 21.73 |
| PBIT Margin (%) | 18.91 | 17.44 | 19.14 | 19.69 | 15.81 |
| PBT Margin (%) | 15.72 | 16.48 | 18.07 | 18.65 | 13.73 |
| Net Profit Margin (%) | 11.70 | 12.32 | 13.52 | 13.50 | 10.09 |
| NP After MI And SOA Margin (%) | 11.70 | 12.32 | 13.52 | 13.50 | 10.09 |
| Return on Networth / Equity (%) | 21.52 | 23.19 | 24.99 | 26.88 | 17.08 |
| Return on Capital Employeed (%) | 20.54 | 30.43 | 32.10 | 33.24 | 22.09 |
| Return On Assets (%) | 9.72 | 14.33 | 15.48 | 15.72 | 9.97 |
| Long Term Debt / Equity (X) | 0.64 | 0.03 | 0.05 | 0.12 | 0.16 |
| Total Debt / Equity (X) | 0.67 | 0.06 | 0.13 | 0.17 | 0.21 |
| Asset Turnover Ratio (%) | 1.05 | 1.31 | 1.27 | 1.09 | 0.82 |
| Current Ratio (X) | 3.22 | 2.10 | 2.03 | 1.98 | 1.99 |
| Quick Ratio (X) | 2.64 | 1.51 | 1.54 | 1.52 | 1.53 |
| Inventory Turnover Ratio (X) | 3.21 | 4.17 | 4.16 | 5.70 | 4.47 |
| Interest Coverage Ratio (X) | 11.60 | 21.76 | 22.31 | 22.88 | 10.43 |
| Interest Coverage Ratio (Post Tax) (X) | 7.72 | 13.92 | 13.72 | 14.07 | 5.85 |
| Enterprise Value (Cr.) | 1909.20 | 1168.47 | 599.62 | 542.92 | 119.61 |
| EV / Net Operating Revenue (X) | 5.27 | 3.95 | 2.64 | 2.95 | 1.03 |
| EV / EBITDA (X) | 23.56 | 19.04 | 11.13 | 12.49 | 4.74 |
| MarketCap / Net Operating Revenue (X) | 5.31 | 4.01 | 2.65 | 2.96 | 0.99 |
| Price / BV (X) | 9.76 | 7.55 | 4.90 | 5.89 | 1.68 |
| Price / Net Operating Revenue (X) | 5.31 | 4.01 | 2.65 | 2.96 | 0.99 |
| EarningsYield | 0.02 | 0.03 | 0.05 | 0.04 | 0.10 |
After reviewing the key financial ratios for Beta Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 54.42. This value is within the healthy range. It has increased from 48.08 (Mar 24) to 54.42, marking an increase of 6.34.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 195.25. It has increased from 163.43 (Mar 24) to 195.25, marking an increase of 31.82.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 195.25. It has increased from 163.43 (Mar 24) to 195.25, marking an increase of 31.82.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 358.96. It has increased from 307.59 (Mar 24) to 358.96, marking an increase of 51.37.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 80.28. This value is within the healthy range. It has increased from 63.82 (Mar 24) to 80.28, marking an increase of 16.46.
- For PBIT / Share (Rs.), as of Mar 25, the value is 67.89. This value is within the healthy range. It has increased from 53.65 (Mar 24) to 67.89, marking an increase of 14.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 56.44. This value is within the healthy range. It has increased from 50.71 (Mar 24) to 56.44, marking an increase of 5.73.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For PBDIT Margin (%), as of Mar 25, the value is 22.36. This value is within the healthy range. It has increased from 20.74 (Mar 24) to 22.36, marking an increase of 1.62.
- For PBIT Margin (%), as of Mar 25, the value is 18.91. This value is within the healthy range. It has increased from 17.44 (Mar 24) to 18.91, marking an increase of 1.47.
- For PBT Margin (%), as of Mar 25, the value is 15.72. This value is within the healthy range. It has decreased from 16.48 (Mar 24) to 15.72, marking a decrease of 0.76.
- For Net Profit Margin (%), as of Mar 25, the value is 11.70. This value exceeds the healthy maximum of 10. It has decreased from 12.32 (Mar 24) to 11.70, marking a decrease of 0.62.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.70. This value is within the healthy range. It has decreased from 12.32 (Mar 24) to 11.70, marking a decrease of 0.62.
- For Return on Networth / Equity (%), as of Mar 25, the value is 21.52. This value is within the healthy range. It has decreased from 23.19 (Mar 24) to 21.52, marking a decrease of 1.67.
- For Return on Capital Employeed (%), as of Mar 25, the value is 20.54. This value is within the healthy range. It has decreased from 30.43 (Mar 24) to 20.54, marking a decrease of 9.89.
- For Return On Assets (%), as of Mar 25, the value is 9.72. This value is within the healthy range. It has decreased from 14.33 (Mar 24) to 9.72, marking a decrease of 4.61.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.64. This value is within the healthy range. It has increased from 0.03 (Mar 24) to 0.64, marking an increase of 0.61.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.67. This value is within the healthy range. It has increased from 0.06 (Mar 24) to 0.67, marking an increase of 0.61.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.05. It has decreased from 1.31 (Mar 24) to 1.05, marking a decrease of 0.26.
- For Current Ratio (X), as of Mar 25, the value is 3.22. This value exceeds the healthy maximum of 3. It has increased from 2.10 (Mar 24) to 3.22, marking an increase of 1.12.
- For Quick Ratio (X), as of Mar 25, the value is 2.64. This value exceeds the healthy maximum of 2. It has increased from 1.51 (Mar 24) to 2.64, marking an increase of 1.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.21. This value is below the healthy minimum of 4. It has decreased from 4.17 (Mar 24) to 3.21, marking a decrease of 0.96.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.60. This value is within the healthy range. It has decreased from 21.76 (Mar 24) to 11.60, marking a decrease of 10.16.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.72. This value is within the healthy range. It has decreased from 13.92 (Mar 24) to 7.72, marking a decrease of 6.20.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,909.20. It has increased from 1,168.47 (Mar 24) to 1,909.20, marking an increase of 740.73.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.27. This value exceeds the healthy maximum of 3. It has increased from 3.95 (Mar 24) to 5.27, marking an increase of 1.32.
- For EV / EBITDA (X), as of Mar 25, the value is 23.56. This value exceeds the healthy maximum of 15. It has increased from 19.04 (Mar 24) to 23.56, marking an increase of 4.52.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.31. This value exceeds the healthy maximum of 3. It has increased from 4.01 (Mar 24) to 5.31, marking an increase of 1.30.
- For Price / BV (X), as of Mar 25, the value is 9.76. This value exceeds the healthy maximum of 3. It has increased from 7.55 (Mar 24) to 9.76, marking an increase of 2.21.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.31. This value exceeds the healthy maximum of 3. It has increased from 4.01 (Mar 24) to 5.31, marking an increase of 1.30.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Beta Drugs Ltd:
- Net Profit Margin: 11.7%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 20.54% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 21.52% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 37 (Industry average Stock P/E: 52.67)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.67
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.7%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Village Nandpur, Baddi Himachal Pradesh 174101 | cs@betadrugslimited.com http://www.betadrugslimited.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rahul Batra | Chairperson & Managing Director |
| Mr. Varun Batra | Joint Managing Director |
| Mrs. Seema Chopra | Whole Time Director |
| Mr. Balwant Singh | Whole Time Director |
| Mr. Manmohan Khanna | Independent Director |
| Mr. Ashutosh Shukla | Whole Time Director |
| Mr. Rohit Parti | Independent Director |
FAQ
What is the intrinsic value of Beta Drugs Ltd?
Beta Drugs Ltd's intrinsic value (as of 27 November 2025) is 1712.52 which is 3.16% higher the current market price of 1,660.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 1,675 Cr. market cap, FY2025-2026 high/low of 2,190/1,430, reserves of ₹211 Cr, and liabilities of 488 Cr.
What is the Market Cap of Beta Drugs Ltd?
The Market Cap of Beta Drugs Ltd is 1,675 Cr..
What is the current Stock Price of Beta Drugs Ltd as on 27 November 2025?
The current stock price of Beta Drugs Ltd as on 27 November 2025 is 1,660.
What is the High / Low of Beta Drugs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Beta Drugs Ltd stocks is 2,190/1,430.
What is the Stock P/E of Beta Drugs Ltd?
The Stock P/E of Beta Drugs Ltd is 37.0.
What is the Book Value of Beta Drugs Ltd?
The Book Value of Beta Drugs Ltd is 219.
What is the Dividend Yield of Beta Drugs Ltd?
The Dividend Yield of Beta Drugs Ltd is 0.00 %.
What is the ROCE of Beta Drugs Ltd?
The ROCE of Beta Drugs Ltd is 27.0 %.
What is the ROE of Beta Drugs Ltd?
The ROE of Beta Drugs Ltd is 25.9 %.
What is the Face Value of Beta Drugs Ltd?
The Face Value of Beta Drugs Ltd is 10.0.